ERAS
Price
$1.74
Change
+$0.03 (+1.75%)
Updated
Jul 25 closing price
Capitalization
492.92M
11 days until earnings call
OLMA
Price
$4.71
Change
+$0.14 (+3.06%)
Updated
Jul 25 closing price
Capitalization
322.26M
16 days until earnings call
Interact to see
Advertisement

ERAS vs OLMA

Header iconERAS vs OLMA Comparison
Open Charts ERAS vs OLMABanner chart's image
Erasca
Price$1.74
Change+$0.03 (+1.75%)
Volume$654.4K
Capitalization492.92M
Olema Pharmaceuticals
Price$4.71
Change+$0.14 (+3.06%)
Volume$490.27K
Capitalization322.26M
ERAS vs OLMA Comparison Chart in %
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OLMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. OLMA commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Buy and OLMA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (ERAS: $1.74 vs. OLMA: $4.71)
Brand notoriety: ERAS and OLMA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 56% vs. OLMA: 66%
Market capitalization -- ERAS: $492.92M vs. OLMA: $322.26M
ERAS [@Biotechnology] is valued at $492.92M. OLMA’s [@Biotechnology] market capitalization is $322.26M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileOLMA’s FA Score has 1 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • OLMA’s FA Score: 1 green, 4 red.
According to our system of comparison, ERAS is a better buy in the long-term than OLMA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 5 TA indicator(s) are bullish while OLMA’s TA Score has 7 bullish TA indicator(s).

  • ERAS’s TA Score: 5 bullish, 5 bearish.
  • OLMA’s TA Score: 7 bullish, 2 bearish.
According to our system of comparison, OLMA is a better buy in the short-term than ERAS.

Price Growth

ERAS (@Biotechnology) experienced а +16.00% price change this week, while OLMA (@Biotechnology) price change was +6.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.62%. For the same industry, the average monthly price growth was +17.39%, and the average quarterly price growth was +28.36%.

Reported Earning Dates

ERAS is expected to report earnings on Nov 05, 2025.

OLMA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+7.62% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($493M) has a higher market cap than OLMA($322M). OLMA YTD gains are higher at: -19.211 vs. ERAS (-30.677). OLMA has higher annual earnings (EBITDA): -142.36M vs. ERAS (-150.24M). OLMA has more cash in the bank: 393M vs. ERAS (305M). OLMA has less debt than ERAS: OLMA (1.15M) vs ERAS (50.8M). ERAS (0) and OLMA (0) have equivalent revenues.
ERASOLMAERAS / OLMA
Capitalization493M322M153%
EBITDA-150.24M-142.36M106%
Gain YTD-30.677-19.211160%
P/E RatioN/AN/A-
Revenue00-
Total Cash305M393M78%
Total Debt50.8M1.15M4,425%
TECHNICAL ANALYSIS
Technical Analysis
ERASOLMA
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 18 days ago
84%
Declines
ODDS (%)
Bearish Trend 16 days ago
88%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
87%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OLMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GUSYX20.560.21
+1.03%
Grandeur Peak US Stalwarts Institutional
SBQUX13.390.12
+0.90%
AmericaFirst Alpha Trends Factor Class U
ANOAX20.770.12
+0.58%
American Century Small Cap Growth A
GABGX126.580.55
+0.44%
Gabelli Growth AAA
ADGGX24.860.11
+0.44%
American Century Disciplined Growth R5

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+1.75%
XNCR - ERAS
54%
Loosely correlated
N/A
RVMD - ERAS
53%
Loosely correlated
+1.84%
LRMR - ERAS
52%
Loosely correlated
+3.47%
OCUL - ERAS
51%
Loosely correlated
+2.43%
BEAM - ERAS
51%
Loosely correlated
+3.68%
More

OLMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, OLMA has been loosely correlated with ATXS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if OLMA jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OLMA
1D Price
Change %
OLMA100%
+3.06%
ATXS - OLMA
48%
Loosely correlated
+1.37%
BEAM - OLMA
47%
Loosely correlated
+3.68%
IDYA - OLMA
44%
Loosely correlated
-1.33%
ERAS - OLMA
44%
Loosely correlated
+1.75%
CRSP - OLMA
44%
Loosely correlated
-1.97%
More